{"id":10488,"date":"2025-12-17T10:42:05","date_gmt":"2025-12-17T10:42:05","guid":{"rendered":"https:\/\/organonpro.com\/en-us\/product\/nexplanon\/about-nexplanon\/safety-including-bleeding-changes\/"},"modified":"2026-01-28T14:25:44","modified_gmt":"2026-01-28T14:25:44","slug":"safety-including-bleeding-changes","status":"publish","type":"product","link":"https:\/\/organonpro.com\/en-us\/product\/nexplanon\/about-nexplanon\/safety-including-bleeding-changes\/","title":{"rendered":"Safety Including Bleeding Pattern Changes"},"content":{"rendered":"\n

About NEXPLANON<\/p>\n\n\n\n

\"Page<\/figure>\n\n\n
\n
\"Page<\/figure><\/div>\n\n\n
<\/div>\n\n\n\n

Select topic below to jump to specific section<\/p>\n\n\n\n

Safety tables ><\/a>     Bleeding pattern changes ><\/a><\/mark> <\/strong><\/p>\n\n\n\n

<\/div>\n\n\n\n
\n\n\n\n

The safety of NEXPLANON was assessed in the 3-year clinical studies and the extended use study. In the 3-year studies:<\/h2>\n\n\n\n
<\/div>\n\n\n\n

Common Adverse Reactions Reported by \u22655% of Subjects in 3-Year Clinical Trials of the Non-Radiopaque Etonogestrel Implant (IMPLANON\u00ae<\/sup>)<\/h3>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\"Table<\/figure>\n\n\n\n
\"Table<\/figure>\n<\/div>\n\n\n\n
\n
\"Table<\/figure>\n\n\n\n
\"Table<\/figure>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Adverse Reactions Leading to Discontinuation of Treatment in 1% or More of Subjects in 3-Year Clinical Trials of the Non-Radiopaque Etonogestrel Implant (IMPLANON\u00ae<\/sup>)<\/h3>\n\n\n\n
<\/div>\n\n\n
\n
\"Table<\/figure><\/div>\n\n
\n
\"Table<\/figure><\/div>\n\n\n
<\/div>\n\n\n\n

a<\/sup>Includes \u201cfrequent,\u201d \u201cheavy,\u201d \u201cprolonged,\u201d \u201cspotting,\u201d and other patterns of bleeding irregularity.\u2028
b<\/sup>Among US subjects (N=330), 6.1% experienced emotional lability that led to discontinuation.
c<\/sup>Among US subjects (N=330), 2.4% experienced depression that led to discontinuation.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n

In the extended use study, a similar adverse reaction profile was observed as in years 1 through 3<\/h2>\n\n\n\n
<\/div>\n\n\n\n

The most frequently reported adverse reaction (>5%) related to NEXPLANON was intermenstrual bleeding (5.4%), Changes in menstrual bleeding patterns were the most frequently reported adverse reaction leading to discontinuation occurring in 4.0% of participants.<\/p>\n\n\n\n

<\/div>\n\n\n
\n
\n
\n
\n
\n
\n

\n